Article
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Clinical lung cancer - 1 May 2018
Reck Martin, Garon Edward B, Paz-Ares Luis, Ponce Santiago, Jaime Jesus Corral, Juan Oscar, Nadal Ernest, Kiura Katsuyuki, Widau Ryan C, He Shuang, Dalal Rita, Lee Pablo, Nakagawa Kazuhiko
Abstract excerpt
BACKGROUND: Despite the likelihood of an initial response to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer (NSCLC) patients develop disease progression. Antiangiogenic agents in combination with an EGFR TKI might provide additional benefit in patients with EGFR-mutant NSCLC. In this article we report safety, exposure, and progression-free...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.